RankAlpha logo
Back to Rankings

NERV

Minerva NeurosciencesB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
The constructive case is that Minerva has moved from planning into active Phase 3 execution, has FDA-aligned trial design language in company materials, and retains differentiated positioning in an area with no approved treatment for negative symptoms of schizophrenia [#SEC-8K-2026-03-11] [#SEC-8K-2026-05-05].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -5.6.
What can break
Dilution and warrant overhang remain relevant even after the October 2025 financing package.
Momentum
86
Value
41
Sentiment
52
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.50 · Bull $7.00 · Bear $2.50
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-22 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $9.50
Why
Momentum86 · Δ7d -5.6
Value41 · Δ7d -0.1
Sentiment52 · Δ7d +5.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
86
26% active weight
Current posture
7d trendSoftening
Δ7d
-5.6
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.7
Sentiment
52
34% active weight
Current posture
7d trendImproving
Δ7d
+5.4
Δ21d
-
Why this grade

Composite grade B. Momentum 85.6 / Value 41.1 / Sentiment 51.9

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$198.93M
Beta
-0.24
Shares Out
46.59M
P/E (TTM)
2.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-3.61
Rev YoY
-100.0%
EPS YoY
+476.2%
Gross Margin
-
Op Margin
-
Net Debt
-$17.44M
Current Ratio
17.65
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology